Dynamic circulating biomarkers for predicting adverse events in PRaG therapy: a pooled analysis and model construction from PRaG series clinical trials

A pooled analysis studied whether circulating immune markers could help identify patients at risk of moderate-to-severe adverse events.

Cancer immunology, immunotherapy : CII · Jan 27, 2026
Original authors: Wei-Wu Chen, Shi-Cheng Li, Qian Yin, Mei-Ling Xu, Jun-Jun Zhang, Xiang-Rong Zhao, Peng-Fei Xing, Yue-Hong Kong, Li-Yuan Zhang

Read the results alongside the study design, safety findings and limitations.

Who was studied?

203 patients from PRaG-series clinical studies.

What does the publication report?

A model incorporating immune-cell measures showed improved discrimination with internal validation. This is a prediction study, not a new efficacy trial.

Safety findings

The modeled endpoint was grade 2 or higher treatment-related adverse events.

How should we interpret it?

Internal validation does not establish external clinical utility. Pooled patients may overlap with other PRaG publications.

Read the original source

This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.

Dynamic circulating biomarkers for predicting adverse events in PRaG therapy: a pooled analysis and model construction from PRaG series clinical trials · DOI: 10.1007/s00262-025-04292-w · PMID: 41591538

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.